Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections
Rujipas Sirijatuphat, Visanu Thamlikitkul, Rujipas Sirijatuphat, Visanu Thamlikitkul
Abstract
Ninety-four patients infected with carbapenem-resistant Acinetobacter baumannii were randomized to receive colistin alone or colistin plus fosfomycin for 7 to 14 days. The patients who received combination therapy had a significantly more favorable microbiological response and a trend toward more favorable clinical outcomes and lower mortality than those who received colistin alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01297894.).
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Source: PubMed